677 related articles for article (PubMed ID: 34519567)
1. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger RF; Unterwald EM
J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
3. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
[TBL] [Abstract][Full Text] [Related]
4. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
5. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Muttoni S; Ardissino M; John C
J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
[TBL] [Abstract][Full Text] [Related]
6. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
7. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
9. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
10. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
Bender D; Hellerstein DJ
Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
[TBL] [Abstract][Full Text] [Related]
11. Psychedelics and Personality.
Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
[TBL] [Abstract][Full Text] [Related]
12. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
13. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
14. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
[TBL] [Abstract][Full Text] [Related]
16. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół A
Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
[TBL] [Abstract][Full Text] [Related]
18. The promises and perils of psychedelic pharmacology for psychiatry.
McClure-Begley TD; Roth BL
Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
[TBL] [Abstract][Full Text] [Related]
19. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
20. Psychedelics and mental health: a population study.
Krebs TS; Johansen PØ
PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]